about
A Possible Role of Intestinal Microbiota in the Pathogenesis of Ankylosing SpondylitisToll-like receptor 2 and 4 induced interleukin-19 dampens immune reactions and associates inversely with spondyloarthritis disease activityRIPK3 promotes cell death and NLRP3 inflammasome activation in the absence of MLKLMonosodium urate crystal deposition associated with the progress of radiographic grade at the sacroiliac joint in axial SpA: a dual-energy CT study.Drug retention rates and treatment discontinuation among anti-TNF-α agents in psoriatic arthritis and ankylosing spondylitis in clinical practice.Anti-inflammatory activity of extracts of Bushen-Qiangdu-Zhilv decoction, a Chinese medicinal formula, in M1-polarized RAW264.7.Update on ankylosing spondylitis: current concepts in pathogenesis.The role of IL-1β in the bone loss during rheumatic diseases.The danger model approach to the pathogenesis of the rheumatic diseases.Activation of the JAK/STAT pathway in Behcet's disease.Expression of Lectin-Like Transcript 1, the Ligand for CD161, in Rheumatoid Arthritis.The Effect of Cigarette Smoke Exposure on the Development of Inflammation in Lungs, Gut and Joints of TNFΔARE MiceThe involvement and possible mechanism of pro-inflammatory tumor necrosis factor alpha (TNF-α) in thoracic ossification of the ligamentum flavumIL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patientsReview: Enthesitis: New Insights Into Pathogenesis, Diagnostic Modalities, and Treatment.Anti-IL17A in Axial Spondyloarthritis-Where Are We At?Classical and Paradoxical Effects of TNF-α on Bone Homeostasis.Pulmonary, renal and neurological comorbidities in patients with ankylosing spondylitis; implications for clinical practice.Vitamin D and spondyloarthritis.IL-23 responsive innate-like T cells in spondyloarthritis: the less frequent they are, the more vital they appear.The IL-23-IL-17 axis in inflammatory arthritis.The genomic landscape of human immune-mediated diseases.Analysis of clinical trials of biosimilar infliximab (CT-P13) and comparison against historical clinical studies with the infliximab reference medicinal product.Innate Immune Activation Can Trigger Experimental Spondyloarthritis in HLA-B27/Huβ2m Transgenic Rats.Infusion of umbilical cord mesenchymal stem cells alleviates symptoms of ankylosing spondylitis.Recurrent macrophage activation syndrome since toddler age in an adolescent boy with HLA B27 positive juvenile ankylosing spondylitis.Cytokine profiles in axial spondyloarthritis.Efficacy and safety of ustekinumab in psoriatic arthritis patients with peripheral arthritis and physician-reported spondylitis: post-hoc analyses from two phase III, multicentre, double-blind, placebo-controlled studies (PSUMMIT-1/PSUMMIT-2).Clinical and Imaging Signs of Spondyloarthritis in First-Degree Relatives of HLA-B27-Positive Ankylosing Spondylitis Patients: The Pre-Spondyloarthritis (Pre-SpA) Cohort Study.Ankylosing spondylitis and the risk of cancer.Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohortGenetic variations in LIGHT are associated with susceptibility to ankylosing spondylitis in a Chinese Han population.Osteoimmunology: The Conceptual Framework Unifying the Immune and Skeletal Systems.Hematopoietic and mesenchymal stem cells: a promising new therapy for spondyloarthritis?Interleukin-22 drives the proliferation, migration and osteogenic differentiation of mesenchymal stem cells: a novel cytokine that could contribute to new bone formation in spondyloarthropathies.Correlation of serum MMP3 and other biomarkers with clinical outcomes in patients with ankylosing spondylitis: a pilot study.Regulation of Cytokine Production by the Unfolded Protein Response; Implications for Infection and Autoimmunity.Therapies in ankylosing spondylitis-from clinical trials to clinical practice
P2860
Q28069331-21F53E3F-8917-43BE-95E6-ADF674709D17Q28256275-B02857DD-FD56-42CA-9B73-04886439C317Q30623992-8379C109-38E8-4BFA-90AE-16BDE910AEC9Q33630612-849BCA74-BBD5-4252-A686-960A34878F14Q33993099-C64C9240-4E83-4397-A668-510D04BC7FA7Q34045249-C4140FCA-2D1C-461C-87DE-A61C9925CA1AQ34450732-7445C9A2-067C-4AA2-B71E-4764B8A62F49Q35540844-2F6184BF-8AE9-44E0-A1BB-41B50F20F956Q35564107-7F023877-AD13-49FF-B259-0FD649E07E7CQ35647068-BBFB280D-2755-4BEE-BF2B-85AA6105B74AQ35683943-DC7195CF-4A22-4F0D-8F4A-409E7BF2C7B8Q35829049-F2B24EA5-9445-4EFB-9817-2BCFBE9F55B9Q36391120-4DAF9D3E-294B-4239-ADCA-D5BEC2018172Q36611562-F28EA77F-10B0-4379-8528-961EACE64715Q37541327-18F7B835-B491-4F2A-B6DE-A093673080B0Q37590576-60D27A58-C9EE-4A61-97D3-FDA69ABE7B3BQ38193090-CD7C737F-A00F-46F3-9DD8-9A94A023D43FQ38219934-98611705-5443-4923-A4E8-5F8FBA422D0AQ38262855-973C65A5-CA55-4B73-AFC9-6411AEABCBD7Q38421287-96DC0B28-BBCD-4D4D-9BAF-BCCC352CE9F0Q38439641-E145A475-5165-424A-8E9F-B7AC94F74F18Q38569875-3D1C60D0-4CCA-4234-90AD-7E2C4A3B6D01Q38591275-D705BB7D-6A04-4AB5-B359-204B12D0BAE6Q38616684-788D3EAF-7152-4067-AB09-5F910C82AB3FQ38646267-9DAADDE3-4CA5-4A7E-92E6-D72409FBB2DAQ39203211-B663B1DB-F564-4EC9-95CF-9DBC4089FFC5Q39608151-CD17470F-53E7-4A2D-918C-00012D0A318FQ40705952-0292A882-2FB3-4BE2-B7F5-4BB250080F4FQ40741048-CA57C1E5-C985-472A-B797-5DBE6005DD69Q41143557-0ED61E5F-41C5-41F4-951C-610EFF9635E9Q42330283-D6940866-7E7F-448F-B4B6-10EB02D71CDFQ47152632-06F92801-9C4B-42C2-9543-960500DE1BB7Q47944184-4F1467E7-F595-42F9-BA1A-7E599B487450Q50025503-7971B6E7-A5C0-4C5F-9C19-FFA6626FBB03Q51017888-0C15254F-AB2F-4078-8B65-13A9BDF4E292Q53340748-77BE2641-E4BA-4EF1-9D87-C3D12FED7AF2Q55260956-0F39300E-A538-46F8-8C6B-F319BEB2936DQ59125383-94E678EF-9F6D-46EF-94AC-96BB6376AF75
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Inflammatory pathways in spondyloarthritis.
@en
type
label
Inflammatory pathways in spondyloarthritis.
@en
prefLabel
Inflammatory pathways in spondyloarthritis.
@en
P2093
P1433
P1476
Inflammatory pathways in spondyloarthritis.
@en
P2093
Dominique L Baeten
Hulda S Hreggvidsdottir
Troy Noordenbos
P356
10.1016/J.MOLIMM.2013.07.016
P577
2013-08-19T00:00:00Z